ClinicalTrials.gg
RecruitingNCT07479485Updated Jul 28, 2026

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

A Phase 1/2 interventional study of MRG006A and Pucotenlimab in Hepatocellular Carcinoma, sponsored by Lepu Biopharma Co., Ltd.. Recruiting at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Lepu Biopharma Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
318th of 1,038
160 · median 77
Started
2026
with 97 others
Phase 1/2
89 of 1,314
33 open now
Primary completion
2028-04
later than 462 of 560 live
Registered
1,224th of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 318th largest by planned enrollment of the 1,038 interventional ones that give a count, is one of 98 that started in 2026, is one of 89 in phase 1/2, reaches primary completion later than 462 of the 560 other live ones, and was the 1,224th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • MRG006A
  • Pucotenlimab
  • Bevacizumab
  • TKI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and provide written , and comply with the requirements specified in the protocol.
  2. ≥ 3 months.
  3. Must provide tumor tissue specimens for GPC3 testing.
  4. Histologically/ confirmed hepatocellular carcinoma (HCC), Barcelona Clinic Liver Cancer (BCLC) Stage C or Stage B not amenable to curative surgery and/or locoregional therapy.
  5. At least one per version 1.1 (RECIST v1.1) and modified RECIST ().
  6. No prior systemic antineoplastic therapy for unresectable HCC before first dose administration.
  7. (ECOG) performance status of 0 or 1, with no deterioration within 2 weeks prior to first study drug administration.
  8. Adequate organ function as specified.
  9. Negative serum pregnancy test within 7 days prior to first dose (women of ). Pregnant or lactating women are not eligible for this study.
  10. Women of childbearing potential and male patients must agree to use adequate during MRG006A treatment and for 180 days after the last infusion.

Exclusion criteria

Exclusion Criteria:

  1. Prior histologically/ confirmed diagnosis of hepatocellular carcinoma with fibrolamellar, sarcomatoid, cholangiocarcinoma, or other components.
  2. History of hepatic failure or hepatic encephalopathy, or history of liver transplantation.
  3. Pleural effusion, ascites, or pelvic effusion, or pericardial effusion.
  4. Acute or chronic active or infection.
  5. Central nervous system .
  6. Prior locoregional therapy for hepatocellular carcinoma within 4 weeks before first dose administration.
  7. Receipt of within 4 weeks before first dose or planned administration during the study period.
  8. Major surgical procedure within 4 weeks before first dose, or the presence of unhealed wounds, ulcers, or bone fractures.
  9. Uncontrolled or poorly controlled medical conditions.
  10. Toxicities from prior therapy that have not resolved to Grade 0 or 1 before first dose of study treatment.
  11. Severe cardiac insufficiency or cerebrovascular events within 6 months prior, or occurrence of pulmonary embolism, deep vein thrombosis, gastrointestinal perforation and/or fistula, or intestinal obstruction.
  12. Patients with double or multiple primary .
  13. to any component or of the product.
  14. Active or poorly controlled severe infection.
  15. Any severe and/or uncontrolled systemic disease that, in the opinion of the investigator and sponsor, renders the patient unsuitable for participation in this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    MRG006A+Pucotenlimab + Bevacizumab

    Drug: MRG006A · Drug: Pucotenlimab · Drug: Bevacizumab

  • Experimental
    MRG006A+ PD1/VEGF antibody

    Drug: MRG006A · Drug: PD1/VEGF antibody

  • Experimental
    MRG006A+ TKI

    Drug: MRG006A · Drug: TKI

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events

    Proportion of participants experiencing treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: Up to 2 years

  2. Recommended Phase 2 Dose

    Evaluate RP2D based on the safety and efficacy of different dosage cohorts.

    Time frame: 1 year

Secondary outcomes

  1. Peak concentration (Cmax)

    Cmax of ADC, TAb, free payload will be measured.

    Time frame: Up to 2 years

  2. Time to peak (Tmax)

    Tmax of ADC, TAb, free payload will be measured.

    Time frame: Up to 2 years

  3. Area under the concentration versus time curve (AUC)

    AUC of ADC, TAb, free payload will be measured.

    Time frame: Up to 2 years

  4. Half-life time (t1/2)

    t1/2 of ADC, TAb, free payload will be measured.

    Time frame: Up to 2 years

  5. Anti-Drug Antibody characteristics

    Proportion of subjects who develop treatment-emergent anti-drug antibody (ADA) positivity.

    Time frame: Up to 2 years

  6. Objective Response Rate

    Proportion of patients with complete response/partial response assessed by Response Criteria in Solid Tumor version 1.1

    Time frame: 6 months

  7. Disease Control Rate

    Proportion of patients with complete response/partial response and stable disease assessed by Response Criteria in Solid Tumor version 1.1

    Time frame: 6 months

  8. Duration of Response

    The time from the first documentation of objective tumor response (CR or PR) until disease progression or death from any cause

    Time frame: Up to 2 years

  9. Progression-Free Survival

    Time between the start of study treatment and progressive disease or any cause of death

    Time frame: Up to 2 years

07

Study locations

1 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 24 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 18, 2026
StartActual
Apr 8, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2029
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07479485
Lead sponsor
Lepu Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Apr 8, 2026
Primary completion
Apr 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Jul 28, 2026

Study contacts

Program Director
Contact
ra_bj@lepubiopharma.com
86-21- 67680899

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion